BRPI0717320A2 - Triazóis bicíclicos como moduladores de proteína cinase - Google Patents

Triazóis bicíclicos como moduladores de proteína cinase

Info

Publication number
BRPI0717320A2
BRPI0717320A2 BRPI0717320-2A2A BRPI0717320A BRPI0717320A2 BR PI0717320 A2 BRPI0717320 A2 BR PI0717320A2 BR PI0717320 A BRPI0717320 A BR PI0717320A BR PI0717320 A2 BRPI0717320 A2 BR PI0717320A2
Authority
BR
Brazil
Prior art keywords
triazols
bicyclic
protein kinase
kinase modulators
modulators
Prior art date
Application number
BRPI0717320-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Pierre-Yves Bounaud
Christopher Ronald Smith
Elizabeth Anne Jefferson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of BRPI0717320A2 publication Critical patent/BRPI0717320A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0717320-2A2A 2006-10-23 2007-10-18 Triazóis bicíclicos como moduladores de proteína cinase BRPI0717320A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30
PCT/US2007/081841 WO2008051808A2 (en) 2006-10-23 2007-10-18 Bicyclic triazoles as protein kinase modulators

Publications (1)

Publication Number Publication Date
BRPI0717320A2 true BRPI0717320A2 (pt) 2013-10-22

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717320-2A2A BRPI0717320A2 (pt) 2006-10-23 2007-10-18 Triazóis bicíclicos como moduladores de proteína cinase

Country Status (25)

Country Link
US (1) US8507489B2 (OSRAM)
EP (1) EP2084162B1 (OSRAM)
JP (1) JP5378222B2 (OSRAM)
KR (1) KR20090071612A (OSRAM)
AR (1) AR063520A1 (OSRAM)
AU (1) AU2007309149C1 (OSRAM)
BR (1) BRPI0717320A2 (OSRAM)
CA (1) CA2667428A1 (OSRAM)
CO (1) CO6190620A2 (OSRAM)
CR (1) CR10803A (OSRAM)
DK (1) DK2084162T3 (OSRAM)
EA (1) EA200970403A1 (OSRAM)
ES (1) ES2393130T3 (OSRAM)
IL (1) IL197958A0 (OSRAM)
MA (1) MA30871B1 (OSRAM)
MX (1) MX2009004059A (OSRAM)
NO (1) NO20091618L (OSRAM)
NZ (1) NZ575336A (OSRAM)
PE (1) PE20080893A1 (OSRAM)
PL (1) PL2084162T3 (OSRAM)
PT (1) PT2084162E (OSRAM)
SV (1) SV2009003235A (OSRAM)
TN (1) TN2009000142A1 (OSRAM)
TW (1) TW200835492A (OSRAM)
WO (1) WO2008051808A2 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
EP2719699B1 (en) 2009-12-31 2015-07-08 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
EP2673277A1 (en) * 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
US9062045B2 (en) * 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
WO2013151913A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (en) * 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
WO2014164200A1 (en) 2013-03-13 2014-10-09 Avon Products, Inc Tyrosinase inhibitors
WO2014140073A1 (en) * 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
US9364405B2 (en) 2013-03-13 2016-06-14 Avon Products, Inc. Tyrosinase inhibitors
US20150152122A1 (en) * 2013-03-13 2015-06-04 Avon Products, Inc. Tyrosinase inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
US9512121B2 (en) 2013-05-10 2016-12-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
EP0228061A3 (en) * 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
EP1575959B1 (en) * 2002-12-18 2010-07-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
CA2573573A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EA011725B1 (ru) 2004-08-26 2009-04-28 Пфайзер Инк. Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
BRPI0519508A2 (pt) 2004-12-27 2009-03-17 Alcon Inc análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase

Also Published As

Publication number Publication date
TW200835492A (en) 2008-09-01
JP2010507578A (ja) 2010-03-11
SV2009003235A (es) 2009-10-15
CA2667428A1 (en) 2008-05-02
AU2007309149B2 (en) 2012-09-06
NO20091618L (no) 2009-05-22
TN2009000142A1 (en) 2010-10-18
MA30871B1 (fr) 2009-11-02
WO2008051808A3 (en) 2008-07-24
PL2084162T3 (pl) 2013-01-31
AR063520A1 (es) 2009-01-28
IL197958A0 (en) 2009-12-24
EA200970403A1 (ru) 2009-10-30
US8507489B2 (en) 2013-08-13
EP2084162B1 (en) 2012-09-12
KR20090071612A (ko) 2009-07-01
AU2007309149A1 (en) 2008-05-02
PT2084162E (pt) 2012-10-09
PE20080893A1 (es) 2008-08-26
DK2084162T3 (da) 2012-10-01
NZ575336A (en) 2012-04-27
CR10803A (es) 2009-06-16
US20090258855A1 (en) 2009-10-15
MX2009004059A (es) 2009-04-27
AU2007309149C1 (en) 2013-04-04
JP5378222B2 (ja) 2013-12-25
ES2393130T3 (es) 2012-12-18
WO2008051808A2 (en) 2008-05-02
CO6190620A2 (es) 2010-08-19
EP2084162A2 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
BRPI0717320A2 (pt) Triazóis bicíclicos como moduladores de proteína cinase
BRPI0716549A2 (pt) moduladores de quinase associada de interleucina-1
BRPI0815096A2 (pt) Sulfonamidas como moduladores de trpm8
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
BRPI0508788A (pt) tiadiazolidinonas como inibidores de sqg - 3
BRPI0717035A2 (pt) Moduladores de benzotriazol cinase
SI2303891T1 (sl) Pirazolo kinazolini kot modulatorji aktivnosti protein kinaze
ES1065655Y (es) Helicoptero
EP2259678A4 (en) PROTEIN KINASE MODULATORS
BRPI0917980A2 (pt) subcanalização com aumento de potência
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
BRPI0818380A2 (pt) Combinação de herbicida-protetor
EP1985679A4 (en) laminating adhesive
DK3118220T3 (da) Protein
DK2242743T3 (da) Aminopyrazolderivater
BRPI0815499A2 (pt) Unidade de iluminação de aeronave
BRPI0814971A2 (pt) Proteína
BRPI0718428A2 (pt) Composição de ibuprofeno
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0806571A2 (pt) Fralda com painéis extensores de quadris
EP2116533A4 (en) Glucokinase AKTIVATOR
ZA200902170B (en) Bicyclic triazoles as protein kinase modulators
DK2188291T3 (da) Fusionerede bicykliske pyrimidiner
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
BRPI0921509A2 (pt) inibidor triazolotiadiazol de proteína quinase c-met

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2328 DE 18-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.